During 2018 Q3 the big money sentiment decreased to 1.16. That’s change of 0.18, from 2018Q2’s 1.34. 13 investors sold all, 24 reduced holdings as Paratek Pharmaceuticals, Inc. ratio turned negative. 30 rose positions while 13 funds bought positions. Funds hold 20.75 million shares thus 0.26% less from 2018Q2’s 20.80 million shares.
Roumell Asset Limited Liability has 4.48% invested in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) for 251,766 shs. Vanguard Gru holds 0% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) or 1.39M shs. 1.20 million are held by Armistice Cap Ltd Liability Corporation. Renaissance Techs Limited Co owns 216,849 shs. Amer Grp Inc Inc invested in 0% or 20,894 shs. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 1,688 shs. Barclays Public Ltd Co invested in 11,975 shs or 0% of the stock. Raymond James Svcs Advsr owns 0% invested in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) for 17,267 shs. Moreover, State Common Retirement Fund has 0% invested in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK). Retail Bank Of America De holds 0% in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) or 16,430 shs. Bnp Paribas Arbitrage reported 1,002 shs. Prelude Capital Limited Com reported 584 shs or 0% of all its holdings. Swiss Bank & Trust holds 0% or 46,700 shs. 301,962 are owned by Geode Cap Management Lc. Price T Rowe Assoc Md accumulated 10,450 shs or 0% of the stock.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) increased to $6.76. On Mar, 4 it was posted by Barchart.com. It has $218.24M MC. $13.09M more could be NASDAQ:PRTK valuation at $7.17 share price.

Investors wait Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)’s quarterly earnings on March, 7., Zacks reports. earnings per share of $-0.61 is 21.79 % up from 2018’s $-0.78 EPS. -39.60 % EPS growth is what analysts predict. $-1.01 earnings per share was published for last quarter.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ratings Coverage

A total of 3 analysts rate Paratek Pharmaceuticals (NASDAQ:PRTK) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. The firm has $25 highest and $14 lowest target. The avg target $19 is 181.07% above the last ($6.76) price. (NASDAQ:PRTK) has 3 ratings reports on Mar 4, 2019 according to StockzIntelligence. In Thursday, February 28 report H.C. Wainwright maintained it with “Buy” rating and $25 target. On Thursday, February 28 Ladenburg maintained Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) with “Buy” rating.

For more Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) news announced briefly go to: Seekingalpha.com, Streetinsider.com, Seekingalpha.com, Globenewswire.com or Seekingalpha.com. The titles are as follows: “PRTK: A Time For Reversal? – Seeking Alpha” announced on October 25, 2018, “Baupost’s 13F Shows New Stakes in eBay (EBAY), Akebia (AKBA), CBS (CBS) (more…) – StreetInsider.com” on February 13, 2019, “Piper upgrades Bausch Health in premarket analyst action – Seeking Alpha” with a publish date: January 02, 2019, “Paratek Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 6, 2018 – GlobeNewswire” and the last “Paratek announces FDA approval of NUZYRA – Seeking Alpha” with publication date: October 03, 2018.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States.The firm is valued at $218.24 million. The Company’s lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections , community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea.Last it reported negative earnings. The firm has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP.